Vosoritide not checked
BioMarin Pharmaceutical · BMN 111
FollowEvery change as it happens, and a Monday email
Trials
10 active
18 in total · 7 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.”In the company’s words, NCT03424018 on ClinicalTrials.gov
- Tested for
- Achondroplasia (5 trials), Hypochondroplasia (2 trials), Idiopathic Short Stature
- Main trialPhase 3
- “The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia”In the company’s words, NCT03424018 on ClinicalTrials.gov
- Other names
- BMN 111
Other drugs for Achondroplasia
- NavepegritideAscendis Pharma A/S · Phase 3
- LonapegsomatropinAscendis Pharma Endocrinology Division A/S · Phase 3
- KK8398Kyowa Kirin Co., Ltd. · Phase 3
- BMN 333BioMarin Pharmaceutical · Phase 2/3
- ABSK061Abbisko Therapeutics Co, Ltd · Phase 1/2
- DabogratinibTyra Biosciences, Inc · Phase 2
Coming up7
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Jun 2028Phase 2 trial completes · ClinicalTrials.gov
- Jun 2029Phase 2/3 trial completes · ClinicalTrials.gov
- Jun 2031Phase 3 trial completes · ClinicalTrials.gov
- May 2038Phase 2 trial completes · ClinicalTrials.gov
- Oct 2044Phase 3 trial completes · ClinicalTrials.gov
Changes4
Last 90 days- 13 NovStatus changed: Active, not recruiting to Terminated · ClinicalTrials.gov NCT06668805
- 13 NovCompletion date moved: 2027-03 to 2026-09-16 · ClinicalTrials.gov NCT06668805
- 12 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT06455059
- 12 NovCompletion date moved: 2026-08-01 to 2026-04-23 · ClinicalTrials.gov NCT06455059
Trials18
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Jun 2031 | An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | |
| Phase 3Enrolling by invitation | Oct 2044 | Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia | |
| Phase 2/3Recruiting | Jun 2029 | Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia | |
| Phase 2Recruiting | Jun 2026 | A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature | |
| Phase 2Active, not recruiting | Dec 2027 | A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia | |
| Phase 2Active, not recruiting | Dec 2027 | A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) | |
| Phase 2Recruiting | 30 Jun 2028 | A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months | |
| Phase 2Active, not recruiting | May 2038 | An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia | |
| Phase 3Completed | 30 Oct 2019 | A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | |
| Phase 3Completed | 23 Apr 2026 | Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia | |
| Phase 2Completed | 2 Oct 2017 | A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia | |
| Phase 2Completed | 26 Jan 2022 | A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia | |
| Phase 2Terminated | 16 Sep 2026 | A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | |
| Phase 1Terminated | 14 Jun 2023 | Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants | |
| Phase 2Authorised | not given | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia, Aged 0 to < 36 Months | |
| Phase 3Ended | not given | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children with Hypochondroplasia | |
| Phase 2Ended | not given | A Phase 2, Randomized, Multicenter, Study of Vosoritide in Children with Noonan Syndrome with Inadequate Growth During or After Human Growth Hormone Treatment | |
| Phase 3Authorised | not given | A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children with Hypochondroplasia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026